Serum markers for early detection and staging of prostate cancer. Status report on current and future markers;Serummarker in der früherkennung und dem staging des prostatakarzinoms. Eine bestandsaufnahme aktueller und zukünftiger marker

Urologe - Ausgabe A

Volumn 42, Issue 9, 2003, Pages 1172-1187

  Haese, A ^a   Graefen, M ^b   Palisaar, J ^b   Huland, E ^b   Huland, H ^b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b NONE

Author keywords

Free PSA Isoforms of free PSA; Human kallikrein 2; Prostate cancer; PSA; Serum markers

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TISSUE KALLIKREIN; TUMOR MARKER;

ADULT; AGED; BLOOD; BLOOD LEVEL; CANCER STAGING; CLASSIFICATION; DIAGNOSTIC VALUE; DISEASE MARKER; EARLY DIAGNOSIS; HOSPITALIZATION; HUMAN; LIFE EXPECTANCY; MALE; METHODOLOGY; PATHOLOGY; PREDICTION AND FORECASTING; PREVALENCE; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATE TUMOR; PROSTATITIS; REPRODUCIBILITY; REVIEW; SENSITIVITY AND SPECIFICITY;

HUMANS; MALE; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TISSUE KALLIKREINS; TUMOR MARKERS, BIOLOGICAL;

EID: 0141728396     PISSN: 03402592     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00120-003-0430-4     Document Type: Review

References (99)

1. Becker C, Piironen T, Kiviniemi J et al. (2000) Sensitive and specific immunodetection of human glandular kallikrein 2 in serum. Clin Chem 46: 198-206
2. Becker C, Piironen T, Pettersson K et al. (2000) Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greater. Urology 55: 694-699
3. Benson MC, Whang IS, Olsson CA et al. (1992) The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J Urol 147: 817-821
4. Bjork T, Ljungberg B, Piironen T et al. (1998) Rapid exponential elimination of free prostate-specific antigen contrasts the slow, capacity-limited elimination of PSA complexed to alpha 1-antichymotrypsin from serum. Urology 51: 57-62
5. Brawer MK, Aramburu EAG, Chen GL et al. (1993) The inability of prostate-specific antigen index to enhance the predictive value of prostate specific antigen in the diagnosis of prostatic carcinoma. J Urol: 150: 369
6. Brawer MK, Cheli CD, Neaman IE et al. (2000) Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer. J Urol 163: 1476-1480
7. Carter HB (2001) Rationale for earlier and less frequent prostate cancer screening. Urology 58: 639-641
8. Carter HB, Partin AW, Luderer AA et al. (1997) Percentage of free prostate-specific antigen in sera predicts aggressiveness of prostate cancer a decade before diagnosis. Urology 49: 379-384
9. Carter HB, Pearson JD (1993) PSA velocity for the diagnosis of early prostate cancer. A new concept. Urol Clin North Am 20: 665-670
10. Carter HB, Pearson JD, Metter EJ et al. (1992) Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. Jama 267: 2215-2220
11. Catalona WJ, Mikolajczyk SD, Linton HJ et al. (2003) ProPSA helps to detect more aggressive prostate cancer in the 2-4 ng/ml range. J Urol 169: 290
12. Catalona WJ, Partin AW, Slawin KM et al. (1998) Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. Jama 279: 1542-1547
13. Catalona WJ, Richie JP, Ahmann FR et al. (1994) Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 151: 1283-1290
14. Catalona WJ, Richie JP, de Kernion JB et al. (1994) Comparison of prostate-specific antigen concentration versus prostate-specific antigen density in the early detection of prostate cancer:Receiver operator characteristic curves. J Urol 152: 2031
15. Catalona WJ, Smith DS; Ornstein DK (1997) Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. Jama 277: 1452-1455
16. Catalona WJ, Smith DS, Ratliff TL, Basler JW (1993) Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. Jama 270: 948-954
17. Catalona WJ, Smith DS, Ratliff TL et al. (1991) Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 324: 1156-1161
18. Christensson A, Bjork T, Nilsson O et al. (1993) Serum prostate specific antigen complexed to alpha 1-anti-chymotrypsin as an indicator of prostate cancer. J Urol 150: 100-105
19. Christensson A, Laurell CB, Lilja H (1990) Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem 194: 755-763
20. Christensson A, Lilja H (1994) Complex formation between protein C inhibitor and prostate-specific antigen in vitro and in human semen. Eur J Biochem 220: 45-53
21. Chybowski FM, Keller JJ, Bergstralh EJ, Oesterling JE (1991) Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters. J Urol 145: 313-318
22. Cooner WH, Mosley BR, Rutherford CL Jr et al. (1990) Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. J Urol 143: 1146-1154
23. Darson MF, Pacelli A, Roche P et al. (1999) Human glandular kallikrein 2 expression in prostate adenocarcinoma and lymph node metastases. Urology 53:939-944
24. Darson MF, Pacelli A, Roche P et al. (1997) Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker. Urology 49:857-862
25. Djavan B, Marberger M, Zlotta AR, Schulman CC (1998) PSA, f/tPSA, PSAD, PSA-TZ and PAS-velocity for prostate cancer prediction: A multivariate analysis. J Urol Am 159: 898
26. Djavan B, Remzi M, Schulman CC et al. (2002) Repeat prostate biopsy: who, how and when? A review. Eur Urol 42: 93-103
27. Djavan B, Remzi M, Zlotta AR et al. (2002) Complexed prostate-specific antigen, complexed prostate-specific antigen density of total and transition zone, complexed/total prostate-specific antigen ratio, free-to-total prostate-specific antigen ratio, density of total and transition zone prostate-specific antigen: results of the prospective multicenter European trial. Urology 60 [Suppl 1]: 4-9
28. Ellis WJ, Chetner MP, Preston SD, Brawer MK (1994) Diagnosis of prostatic carcinoma: the yield of serum prostate specific antigen, digital rectal examination and transrectal ultrasonography. J Urol 152: 1520-1525
29. Filella X, Alcover J, Molina R et al. (2000) Measurement of complexed PSA in the differential diagnosis between prostate cancer and benign prostate hyperplasia. Prostate 42: 181-185
30. Finlay JA, Day JR, Evans CL et al. (2001) Development of a dual monoclonal antibody immunoassay for total human kallikrein 2. Clin Chem 47: 1218-1224
31. Gann PH, Hennekens CH, Stampfer MJ (1995) A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. Jama 273: 289-294
32. Graefen M, Karakiewicz PI, Cagiannos I et al. (2002) Percent free prostate specific antigen is not an independent predictor of organ confinement or prostate specific antigen recurrence in unscreened patients with localized prostate cancer treated with radical prostatectomy. J Urol 167: 1306-1309
33. Haese A, Becker C, Noldus J et al. (2000): Human glandular kallikrein 2: a potential serum marker for predicting the organ confined versus non-organ confined growth of prostate cancer. J Urol 163: 1491-1497
34. Haese A, Dworschack RT, Partin AW (2002) Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml.range. J Urol 168: 504-508
35. Haese A, Graefen M, Noldus J et al. (1997) Prostatic volume and ratio of free-to-total prostate specific antigen in patients with prostatic cancer or benign prostatic hyperplasia. J Urol 158: 2188-2192
36. Haese A, Graefen M, Steuber T et al.(2001) Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml. Prostate 49: 101-109
37. Hammerer P, Huland H (1994) Systematic sextant biopsies in 651 patients referred for prostate evaluation. J Urol 151: 99-102
38. Hara I, Miyake H, Hara S et al. (2001) Value of the serum prostate-specific antigen-alpha 1-antichymotrypsin complex and its density as a predictor for the extent of prostate cancer. BJU Int 88: 53-57
39. Hara M, Koyanagi Y, Inoue T, Fukuyama T (1971) Some physico-chemical characteristics of "gamma-semino-protein", an antigenic component specific for human seminal plasma. Forensic immunological study of body fluids and secretion. VII. Nippon Hoigaku Zasshi 25: 322-324
40. Hoekx L, Jeuris W, Van Marck E, Wyndaele JJ (1998) Flevated serum prostate specific antigen (PSA) related to asymptomatic prostatic inflammation. Acta Urol Belg 66: 1-2
41. Kuriyama M, Wang MC, Lee CI et al. (1981) Use of human prostate-specific antigen in monitoring prostate cancer. Cancer Res 41: 3874-3876
42. Kwiatkowski MK, Recker F, Piironen T et al.(1998) In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic, "gray zone" of total PSA 4 to 10 ng/mL. Urology 52:360-365
43. Leinonen J, Zhang WM, Stenman UH (1996) Complex formation between PSA isoenzymes and protease inhibitors. J Urol 155: 1099-1103
44. Lerner SE, Jacobsen SJ, Lilja H et al. (1996) Free, complexed, and total serum prostate-specific antigen concentrations and their proportions in predicting stage, grade, and deoxyribonucleic acid ploidy in patients with adenocarcinoma of the prostate. Urology 48: 240-248
45. Lilja H, Christensson A, Dahlen U et al. (1991) Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin Chem 37: 1618-1625
46. Lilja H, Haese A, Bjork T et al. (1999) Significance and metabolism of complexed and noncomplexed prostate specific antigen forms, and human glandular kallikrein 2 in clinically localized prostate cancer before and after radical prostatectomy. J Urol 162: 2029-2035
47. Linton HJ, Marks LS, Millar LS et al. (2003) Benign prostate-specific antigen (BPSA) in serum is increased in benign prostate disease. Clin Chem 49: 253-259
48. Lodding P, Aus G, Bergdahl S et al. (1998) Characteristics of screening detected prostate cancer in men 50 to 66 years old with 3 to 4 ng./ml. Prostate specific antigen. J Urol 159: 899-903
49. Lovgren J, Rajakoski K, Karp M et al. (1997) Activation of the zymogen form of prostate-specific antigen by human glandular kallikrein 2. Biochem Biophys Res Commun 238: 549-555
50. Luderer AA, Chen YT, Soriano TF et al. (1995) Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen. Urology 46: 187-194
51. Magklara A, Scorilas A, Catalona WJ, Diamandis EP (1999) The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA. Clin Chem 45: 1960-1966
52. McNeal JE, Villers AA, Redwine EA et al. (1990) Capsular penetration in prostate cancer. Significance for natural history and treatment. Am J Surg Pathol 14: 240-247
53. Mikolajczyk SD, Millar LS, Marker KM et al. (2000) Seminal plasma contains "PSA," a molecular form of prostate-specific antigen that is associated with benign prostatic hyperplasia. Prostate 45: 271-276
54. Mikolajczyk SD, Millar LS, Wang TJ et al. (2000) "BPSA", a specific molecular form of free prostate-specific antigen is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia. Urology 55: 41-45
55. Mikolajczyk SD, Rittenhouse HG (2001) BPSA and pPSA are complementary forms of PSA that are found, respectively, in the serum of men with benign and malignant prostate disease. J Clin Lig Assay (submitted)
56. Miller MC, O'Dowd GJ, Partin AW, Veltri RW (2001) Contemporary use of complexed PSA and calculated percent free PSA for early detection of prostate cancer: impact of changing disease demographics. Urology 57: 1105-1111
57. Mitchell IDC, Croal BL, Dickie A et al. (2001) A prospective study to evaluate the role of complexed prostate-specific antigen and free/total prostate-specific antigen ratio for the diagnosis of prostate cancer. J Urol 165: 1549-1553
58. Nadler RB, Humphrey PA, Smith DS et al. (1995) Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol 154: 407-413
59. Narayan P, Gajendran V, Taylor SP et al. (1995) The role of transrectal ultrasound-guided biopsy-based staging, preoperative serum prostate-specific antigen, and biopsy Gleason score in prediction of final pathologic diagnosis in prostate cancer. Urology 46: 205-212
60. Nixon RG, Wener MH, Smith KMB (1997) Biolgical variation of prostate specific antigen levles in serum: an evaluation of day-to-day physiological fluctuations in a well-defined cohort of 24 patients. J Urol 157: 2183-2190
61. Noldus J, Graefen M, Huland E et al. (1998) The value of the ratio of free-to-total prostate specific antigen for staging purposes in previously untreated prostate cancer. J Urol 159: 2004-2008
62. Nurmikko P, Pettersson K, Piironen T et al.(2001) Discrimination of prostate cancer from benign disease by plasma measurement of intact, free prostate-specific antigen lacking an internal cleavage site at Lys145-Lys146. Clin Chem 47: 1415-1423
63. Nurmikko P, Vaisanen V, Piironen T et al. (2000) Production and charakterisation of novel anti-prostate-specific antigen (PSA) monoclonal antibodies that do not detect internally cleaved Lys145-Lys146 inactive PSA. Clin Chem 46: 1610-1618
64. Oesterling JE (1996) Age-specific reference ranges for serum PSA. N Engl J Med 335: 345-346
65. Oesterling JE, Chan DW, Epstein JI et al. (1988) Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J Urol 139: 766-772
66. Oesterling JE, Rice DC, Glenski WJ, Bergstralh EJ (1993) Effect of cystoscopy, prostate biopsy, and transurethral resection of prostate on serum prostate-specific antigen concentration. Urology 42: 276-282
67. Okegawa T, Noda H, Nutahara K, Higashihara E (2000) Comparison of two investigative assays for the complexed prostate-specific antigen in total prostate-specific antigen between 4.1 and 10 ng/ml. Urology 55: 700-704
68. Okihara K, Fritsche H, Ayala A et al. (2001) Can complexed prostate-specific antigen enhance prostate cancer detection in men with total prostate specific antigen between 2.4 and 4 ng/mI. J Urol 165: 1930-1936
69. Ornstein DK, Smith DS, Humphrey PA, Catalona WJ (1998) The effect of prostate volume, age, total prostate specific antigen level and acute inflammation on the percentage of free serum prostate specific antigen levels in men without clinically detectable prostate cancer. J Urol 159: 1234-1237
70. Papsidero LD, Wang MC, Valenzuela LA et al. (1980) A prostate antigen in sera of prostatic cancer patients. Cancer Res 40: 2428-2432
71. Partin AW, Carter HB, Chan DW et al. (1990) Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol 143: 747-752
72. Partin AW, Catalona WJ, Southwick PC et al. (1996) Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume, and age. Urology 48:55-61
73. Partin AW, Criley SR, Subong EN et al. (1996) Standard versus age-specific prostate-specific antigen reference ranges among men with clinically localized prostate cancer: A pathological analysis. J Urol 155: 1336
74. Partin AW, Mangold LA, Sokoll LJ et al. (2003) Clinical utility of proPSA and BPSA when percent free PSA is below 15%. J Urol 169: 384
75. Partin AW, Yoo J, Carter HB et al. (1993) The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 150: 110-114
76. Piironen T, Lovgren J, Karp M et al. (1996) Immunofluorometric assay for sensitive and specific measurement of human prostatic glandular kallikrein (hK2) in serum. Clin Chem 42: 1034-1041
77. Polascik TJ, Oesterling JE, Partin AW (1999) Prostate specific antigen: a decade of discovery - what we have learned and where we are going. J Urol 162: 293-306
78. Prestigiacomo AF, Lilja H, Pettersson K et al. (1996) A comparison of the free fraction of serum prostate specific antigen in men with benign and cancerous prostates: the best case scenario. J Urol 156: 350-354
79. Recker F, Kwiatkowski MK, Piironen T et al. (2000) Human glandular kallikrein as a tool to improve discrimination of poorly differentiated and non-organ-confined prostate cancer compared with prostate-specific antigen. Urology 55: 481-485
80. Reissigl A, Pointner J, Horniger W et al. (1995) Comparison of different prostate-specific antigen cutpoints for early detection of prostate cancer: Results of a large screening study. Urology 46: 662
81. Ross KS, Carter HB, Pearson JD, Guess HA (2000) Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection. Jama 284: 1399-405
82. Sakr WA, Haas GP, Cassin BF et al. (1993) The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol 150: 379-385
83. Schedlich LJ, Bennetts BH, Morris BJ (1987) Primary structure of a human glandular kallikrein gene. DNA 6: 429-437
84. Schroder FH, Kranse R, Rietbergen J et al. (1999) The European Randomized Study of Screening for Prostate Cancer (ERSPC): an update. Members of the ERSPC, Section Rotterdam. Eur Urol 35: 539-543
85. Schroder FH, van der Cruijsen-Koeter I, de Koning HJ et al. (2000) Prostate cancer detection at low prostate specific antigen. J Urol 163: 806-812
86. Seaman E, Whang IS, Olsson CA et al. (1993) PSA-Density (PSAD). Role in patient evaluation and management. Urol Clin North Am 20: 635
87. Semjonow A, De Angelis G, Schmidt HP (2001) Variability of Immunoassays for PSA,in prostate-specific antigen. Dekker, New York
88. Shariat S, Mikolajczyk SD, Singh H et al. (2003) Preoperative serum levels of proPSA isoforms are associated with biologically aggressive prostate cancer. J Urol 169: 60
89. Sokoll LJ, Chan DW, Mikolajczyk SD et al. (2003) Proenzyme psa for the early detection of prostate cancer in the 2.5-4.0 ng/ml total psa range: preliminary analysis. Urology 61: 274-276
90. Stamey TA, Kabalin JN, McNeal JE et al. (1989) Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. J Urol 141: 1076-1083
91. Stamey TA, Yemoto CE (2000) Examination of the 3 molecular forms of serum prostate specific antigen for distinguishing negative from positive biopsy: relationship to transition zone volume. J Urol 163: 119-126
92. Stenman UH, Leinonen J, Alfthan H et al. (1991) A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 51: 222-226
93. Steuber T, Nurmikko P, Haese A et al. (2002) Discrimination of benign from malignant prostatic disease by selective measurements of single chain, intact free prostate specific antigen. J Urol 168: 1917-1922
94. Takayama TK, Carter CA, Deng T (2001) Activation of prostate-specific antigen precursor (pro-PSA) by prostin, a novel human prostatic serine protease identified by degenerate PCR. Biochemistry 40: 1679-1687
95. Taneja SS, Hsu EI, Cheli CD et al. (2002) Complexed prostate-specific antigen as a staging tool: results based on a multicenter prospective evaluation of complexed prostate-specific antigen in cancer diagnosis. Urology 60 [4 Suppl 1]: 10-17
96. Veltri RW, Miller MC, O'Dowd GJ, Partin AW (2002) Impact of age on total and complexed prostate-specific antigen cutoffs in a contemporary referral series of men with prostate cancer. Urology 60 [4 Suppl 1]: 47-52
97. Wang MC, Valenzuela LA, Murphy GP, Chu TM (1979) Purification of a human prostate specific antigen. Invest Urol 17: 159-163
98. Zhang WM, Finne P, Leinonen J et al. (1998) Characterization and immunological determination of the complex between prostate-specific antigen and alpha2-macroglobulin. Clin Chem 44: 2471-2479
99. Zhang WM, Finne P, Leinonen J et al. (1999) Measurement of the complex between prostate-specific antigen and α1-protease inhibitor in serum. Clin Chem 45: 814-821